Regeneron Pharmaceuticals 将来の成長
Future 基準チェック /16
Regeneron Pharmaceuticals利益と収益がそれぞれ年間11.7%と8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に15% 11.7%なると予測されています。
主要情報
11.7%
収益成長率
11.70%
EPS成長率
| Biotechs 収益成長 | 25.4% |
| 収益成長率 | 8.0% |
| 将来の株主資本利益率 | 14.99% |
| アナリストカバレッジ | Good |
| 最終更新日 | 20 May 2026 |
今後の成長に関する最新情報
Recent updates
Seeking Alpha • May 18
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking Alpha
ナラティブの更新 • May 03
REGN: Expanding Immunology And Gene Therapy Will Support Future Upside
Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.
ナラティブの更新 • Apr 19
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.
ナラティブの更新 • Apr 04
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.ナラティブの更新 • Mar 21
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.ナラティブの更新 • Mar 07
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.
新しいナラティブ • Mar 03
Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.
Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.ナラティブの更新 • Feb 21
REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.ナラティブの更新 • Feb 06
REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.ナラティブの更新 • Jan 23
REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.ナラティブの更新 • Jan 09
REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.ナラティブの更新 • Dec 25
REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.ナラティブの更新 • Dec 11
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.ナラティブの更新 • Nov 27
REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.分析記事 • Nov 19
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...ナラティブの更新 • Nov 12
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.分析記事 • Nov 09
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...ナラティブの更新 • Oct 28
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.ナラティブの更新 • Sep 18
Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 18,940 | 5,788 | 6,899 | 7,040 | 22 |
| 12/31/2027 | 17,553 | 5,133 | 6,090 | 6,277 | 26 |
| 12/31/2026 | 15,880 | 4,088 | 5,055 | 5,696 | 27 |
| 3/31/2026 | 14,920 | 4,423 | 3,791 | 5,013 | N/A |
| 12/31/2025 | 14,343 | 4,505 | 3,765 | 4,979 | N/A |
| 9/30/2025 | 14,248 | 4,578 | 3,881 | 5,071 | N/A |
| 6/30/2025 | 14,214 | 4,459 | 3,556 | 4,744 | N/A |
| 3/31/2025 | 14,086 | 4,499 | 2,962 | 3,953 | N/A |
| 12/31/2024 | 14,202 | 4,413 | 3,539 | 4,421 | N/A |
| 9/30/2024 | 13,847 | 4,655 | 3,319 | 4,247 | N/A |
| 6/30/2024 | 13,489 | 4,322 | 3,184 | 4,071 | N/A |
| 3/31/2024 | 13,100 | 3,858 | 3,930 | 4,739 | N/A |
| 12/31/2023 | 13,117 | 3,954 | 3,668 | 4,594 | N/A |
| 9/30/2023 | 13,097 | 3,991 | 4,359 | 5,224 | N/A |
| 6/30/2023 | 12,671 | 4,299 | 3,004 | 4,739 | N/A |
| 3/31/2023 | 12,370 | 4,183 | 2,527 | 4,281 | N/A |
| 12/31/2022 | 12,173 | 4,338 | 3,398 | 5,015 | N/A |
| 9/30/2022 | 13,710 | 5,370 | 4,148 | 5,668 | N/A |
| 6/30/2022 | 14,227 | 5,687 | 7,869 | 8,452 | N/A |
| 3/31/2022 | 16,508 | 7,934 | 7,936 | 8,515 | N/A |
| 12/31/2021 | 16,072 | 8,075 | 6,529 | 7,081 | N/A |
| 9/30/2021 | 13,543 | 6,996 | 5,381 | 5,940 | N/A |
| 6/30/2021 | 12,384 | 6,205 | 1,694 | 2,272 | N/A |
| 3/31/2021 | 9,198 | 4,004 | 2,029 | 2,589 | N/A |
| 12/31/2020 | 8,497 | 3,513 | 2,004 | 2,618 | N/A |
| 9/30/2020 | 7,938 | 3,156 | 1,582 | 2,175 | N/A |
| 6/30/2020 | 7,387 | 2,984 | 2,425 | 2,986 | N/A |
| 3/31/2020 | 7,013 | 2,279 | 1,706 | 2,231 | N/A |
| 12/31/2019 | 6,558 | 2,116 | N/A | 2,430 | N/A |
| 9/30/2019 | 6,622 | 2,144 | N/A | 2,371 | N/A |
| 6/30/2019 | 6,542 | 2,069 | N/A | 2,267 | N/A |
| 3/31/2019 | 6,572 | 2,428 | N/A | 2,473 | N/A |
| 12/31/2018 | 5,146 | 2,444 | N/A | 2,195 | N/A |
| 9/30/2018 | 6,365 | 1,798 | N/A | 2,033 | N/A |
| 6/30/2018 | 6,203 | 1,591 | N/A | 1,995 | N/A |
| 3/31/2018 | 6,065 | 1,428 | N/A | 1,570 | N/A |
| 12/31/2017 | 5,872 | 1,199 | N/A | 1,307 | N/A |
| 9/30/2017 | 5,517 | 1,278 | N/A | 1,118 | N/A |
| 6/30/2017 | 5,236 | 1,155 | N/A | 1,354 | N/A |
| 3/31/2017 | 4,979 | 963 | N/A | 1,784 | N/A |
| 12/31/2016 | 4,860 | 896 | N/A | 1,486 | N/A |
| 9/30/2016 | 4,732 | 797 | N/A | 1,377 | N/A |
| 6/30/2016 | 4,649 | 743 | N/A | 1,619 | N/A |
| 3/31/2016 | 4,435 | 741 | N/A | 1,477 | N/A |
| 12/31/2015 | 4,104 | 636 | N/A | 1,331 | N/A |
| 9/30/2015 | 3,808 | 571 | N/A | 1,247 | N/A |
| 6/30/2015 | 3,396 | 444 | N/A | 519 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: REGNの予測収益成長率 (年間11.7% ) は 貯蓄率 ( 3.5% ) を上回っています。
収益対市場: REGNの収益 ( 11.7% ) US市場 ( 16.7% ) よりも低い成長が予測されています。
高成長収益: REGNの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: REGNの収益 ( 8% ) US市場 ( 11.7% ) よりも低い成長が予測されています。
高い収益成長: REGNの収益 ( 8% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: REGNの 自己資本利益率 は、3年後には低くなると予測されています ( 15 %)。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 04:49 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Regeneron Pharmaceuticals, Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53
| アナリスト | 機関 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |